After Session 2, participants should be able to:

• Identify which pharmacotherapy options show potential benefit in treating BFRBs
• Identify common co-occurring conditions in HPD and SPD
• Identify when is would be most appropriate to use N-acetyl cysteine, SSRIs and/or other psychotropic agents to treat BFRBs and comorbid conditions
• Describe the psychiatric and medical differential for HPD and SPD, and identify possible medical sequelae from BFRBs